Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289341 · ClinicalTrials.gov registry record · Phase 1
Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00289341 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 24 participants.
The verdict
NCT00289341, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and activity of a type of vaccine as immune therapy for prostate cancer. This vaccine will be made for each participant's own immune cells (called dendritic cells) obtained by blood donation. Dendritic cells are immune cells, whose role is to identify foreign antigens (bacteria, viruses, or tumor cells, for example) in the body and to activate other cells of the immune system to mount an attack on that foreign antigen. Each participant will be randomized into either Arm 1 (experimental treatment only) or Arm 2 (placebo first, then the experimental treatment). Participants will be given the vaccine and three boosters as an injection. After the placebo phase, each participant in Arm 2 will crossover to the treatment phase so that all participants will eventually receive the experimental treatment.
Interventions
- BIOLOGICAL vaccine vehicle only
- BIOLOGICAL DC/LNCaP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00289341
The ClinicalTrials.gov registry entry for NCT00289341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vaccine vehicle only is the first listed.
NCT00289341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00289341 about?
NCT00289341 is a clinical study titled "Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.". The purpose of this study is to assess the safety and activity of a type of vaccine as immune therapy for prostate cancer. This vaccine will be made for each participant's own immune cells (called dendritic cells) obtained by blood donation. Dendritic cells are immune cells, whose role is to identif...
What is the current status of trial NCT00289341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00289341?
The interventions under investigation include: vaccine vehicle only (BIOLOGICAL), DC/LNCaP (BIOLOGICAL).
Who is sponsoring clinical trial NCT00289341?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.